Skip to main content
BMRN
NASDAQ Life Sciences

BioMarin 正式完成 Amicus Therapeutics 收购

feedReported by Dow Jones Newswires
Sentiment info
Neutral
Importance info
7
Price
$53.94
Mkt Cap
$10.228B
52W Low
$50.76
52W High
$66.275
Market data snapshot near publication time

summarizeSummary

BioMarin Pharmaceutical Inc. 已经正式完成了对 Amicus Therapeutics 的收购。这确认了最初在 BioMarin 2 月 10-K 文件中详细说明的重大交易，并在几天前获得了最终的监管批准，如 4 月 23 日的 8-K 和新闻报道中宣布的那样。该交易的完成消除了人们对该交易的任何剩余不确定性，允许 BioMarin 进行 Amicus 资产和业务的整合。交易者现在将关注合并后的实体的更新财务预测、整合进展以及从收购的资产中获得新的产品管道开发的潜力。

在该公告发布时，BMRN的交易价格为$53.94，交易所为NASDAQ，所属行业为Life Sciences，市值约为$102.3亿。 52周交易区间为$50.76至$66.28。 这则新闻被评估为中性市场情绪，重要性评分为7/10。 来源：Dow Jones Newswires。

show_chartPrice Chart

Share this article

Copied!

feed BMRN - Latest Insights

BMRN
Apr 27, 2026, 8:45 AM EDT
Filing Type: 8-K
Importance Score:
9
BioMarin Finalizes $4.8 Billion Acquisition of Amicus Therapeutics, Secures $3.4 Billion in New Debt
Sentiment: Neutral
View Wiseek Article
BMRN
Apr 27, 2026, 8:44 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
BioMarin Officially Closes Amicus Therapeutics Acquisition
Sentiment: Neutral
View Wiseek Article
BMRN
Apr 23, 2026, 4:23 PM EDT
Source: Wiseek News
Importance Score:
8
BioMarin Clears Final French FDI Hurdle for Amicus Merger, Deal Expected to Close April 27
Sentiment: Positive
View Wiseek Article
BMRN
Apr 23, 2026, 4:20 PM EDT
Filing Type: 8-K
Importance Score:
8
BioMarin Secures Final French FDI Clearance for Amicus Therapeutics Merger, Closing Expected April 27
Sentiment: Positive
View Wiseek Article
BMRN
Apr 21, 2026, 4:19 PM EDT
Filing Type: DEF 14A
Importance Score:
8
BioMarin Seeks Shareholder Approval for Significant Equity Plan Expansion and Board Leadership Transition
Sentiment: Negative
View Wiseek Article
BMRN
Mar 16, 2026, 8:38 AM EDT
Source: Reuters
Importance Score:
7
BioMarin Discontinues Multiple Voxzogo Phase 2 Trials Citing Adverse Events
Sentiment: Negative
View Wiseek Article
BMRN
Mar 16, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
8
BioMarin Halts VOXZOGO Phase 2 Trials for Multiple Indications Due to Safety Concerns
Sentiment: Negative
View Wiseek Article
BMRN
Feb 27, 2026, 8:02 PM EST
Source: Reuters
Importance Score:
7
FDA Expands BioMarin's Palynziq Approval to Adolescents with PKU
Sentiment: Positive
View Wiseek Article
BMRN
Feb 26, 2026, 12:30 PM EST
Filing Type: 10-K
Importance Score:
8
BioMarin Reports Full-Year 2025 Results, Details Amicus Acquisition, and ROCTAVIAN Withdrawal
Sentiment: Neutral
View Wiseek Article
BMRN
Feb 23, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
8
BioMarin Reports Mixed Q4/FY25 Results, Withdraws ROCTAVIAN, Issues Strong 2026 EPS Guidance
Sentiment: Neutral
View Wiseek Article